
Johnson & Johnson Seeks FDA Approval for New Ulcerative Colitis Treatment
SPRING HOUSE, PA — Johnson & Johnson announced it recently submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for TREMFYA® (guselkumab). This application …
Johnson & Johnson Seeks FDA Approval for New Ulcerative Colitis Treatment Read More